dc.contributor.author | Santoro, Matteo | |
dc.contributor.author | Maetzler, Walter | |
dc.contributor.author | Stathakos, Petros | |
dc.contributor.author | Martin, Heather L. | |
dc.contributor.author | Hobert, Markus A. | |
dc.contributor.author | Rattray, Tim W. | |
dc.contributor.author | Gasser, Thomas | |
dc.contributor.author | Forrester, John V. | |
dc.contributor.author | Berg, Daniela | |
dc.contributor.author | Tracey, Kevin J. | |
dc.contributor.author | Riedel, Gernot | |
dc.contributor.author | Teismann, Peter | |
dc.date.accessioned | 2016-03-29T15:00:05Z | |
dc.date.available | 2016-03-29T15:00:05Z | |
dc.date.issued | 2016-07 | |
dc.identifier | 62868043 | |
dc.identifier | 81030cfb-7168-46c7-a10c-1ba70c51b88c | |
dc.identifier | 84962520475 | |
dc.identifier.citation | Santoro , M , Maetzler , W , Stathakos , P , Martin , H L , Hobert , M A , Rattray , T W , Gasser , T , Forrester , J V , Berg , D , Tracey , K J , Riedel , G & Teismann , P 2016 , ' In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin ' , Neurobiology of Disease , vol. 91 , pp. 59-68 . https://doi.org/10.1016/j.nbd.2016.02.018 | en |
dc.identifier.issn | 0969-9961 | |
dc.identifier.uri | http://hdl.handle.net/2164/5783 | |
dc.description | Acknowledgements Samples were obtained from the Neuro Biobank of the University of Tuebingen, Germany (http://www.hih-tuebingen.de/nd/biobank/for-researchers/). This biobank is supported by the Hertie Institute and the DZNE. We are grateful to the staff of the Medical Research Facility for their help with the animal care. We thank Dr. Kinnari Sathe for her help with the experiments. We thank Claire A. Walker for assisting with western blot analysis. This study was supported by: Tenovus Scotland, Parkinson's Disease Foundation, Royal Society 2006/R1, NHS Endowment 14-42, and Wellcome Trust WT080782MF. | en |
dc.format.extent | 10 | |
dc.format.extent | 2990444 | |
dc.language.iso | eng | |
dc.relation.ispartof | Neurobiology of Disease | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | Parkinson's disease | en |
dc.subject | MPTP | en |
dc.subject | High-mobility group box 1 | en |
dc.subject | receptor for advanced glycation endproducts | en |
dc.subject | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry | en |
dc.subject | Wellcome Trust | en |
dc.subject | WT080782MF | en |
dc.subject.lcc | RC0321 | en |
dc.title | In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Medicine, Medical Sciences & Nutrition | en |
dc.contributor.institution | University of Aberdeen.Medical Sciences | en |
dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.1016/j.nbd.2016.02.018 | |